Everolimus-related organizing pneumonia: a report establishing causality
- 217 Downloads
Everolimus (RAD001) is an oral mTOR inhibitor that belongs to the group of proliferation signal inhibitors (PSI), which also includes sirolimus and temsirolimus. These compounds have antiproliferative and antifibrotic properties, and were initially used as immunosuppressants in solid organ transplantation. Their pleiotropic effects led to their use in cancer therapy. Drug-related pneumonias were first described in subjects treated with sirolimus , but subsequent reports suggested that everolimus could also cause pneumonia [2, 3, 4, 5, 6]. However, all cases of everolimus-related pneumonia have been reported in subjects (i.e. transplant recipients or subjects with advanced cancers), who had received multiple therapies or who had pre-existing pulmonary disease (e.g. lung cancer). This has led to difficulties in establishing a firm causal relationship. We report a case of everolimus-related organizing pneumonia in a subject without pre-existing pulmonary disease or...
KeywordsEverolimus Sirolimus Ramipril Autosomal Dominant Polycystic Kidney Disease Temsirolimus
- 7.Walz G, Budde K, Mannaa M, Nurnberger J, Wanner C, Sommerer C, Kunzendorf U, Banas B, Horl WH, Obermuller N, Arns W, Pavenstadt H, Gaedeke J, Buchert M, May C, Gschaidmeier H, Kramer S, Eckardt KU (2010) Everolimus in patients with autosomal dominant polycystic kidney disease. N Engl J Med 363:830–840Google Scholar
- 10.Ellard SL, Clemons M, Gelmon KA, Norris B, Kennecke H, Chia S, Pritchard K, Eisen A, Vandenberg T, Taylor M, Sauerbrei E, Mishaeli M, Huntsman D, Walsh W, Olivo M, McIntosh L, Seymour L (2009) Randomized phase II study comparing two schedules of everolimus in patients with recurrent/metastatic breast cancer: NCIC Clinical Trials Group IND.163. J Clin Oncol 27:4536–4541PubMedCrossRefGoogle Scholar
- 11.O’Donnell A, Faivre S, Burris HA 3rd, Rea D, Papadimitrakopoulou V, Shand N, Lane HA, Hazell K, Zoellner U, Kovarik JM, Brock C, Jones S, Raymond E, Judson I (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 26:1588–1595PubMedCrossRefGoogle Scholar
- 12.Montagnino G, Sandrini S, Casciani C, Schena FP, Carmellini M, Civati G, Rigotti P, Cossu M, Altieri P, Salvadori M, Federico S, Stefoni S, Cambi V, Albertazzi A, Buoncristiani U, Berloco P, Segoloni G, Boschiero L, Sparacino V, Donati D, Turello E, Dal Canton A, Ponticelli C (2005) A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine. Transplant Proc 37:788PubMedCrossRefGoogle Scholar